SecBot SecBot
DEFA14A ·Filed Jul 6, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 5/10
Horizondays Processed4mo ago SEC0001213900-26-075169
Actionable Insight • Neutral

The proxy fight is settled, removing near-term overhang. Watch for the identity and background of the mutually agreed New Director within 90 days post-meeting, a credible independent biotech operator would signal continued governance improvement. The standstill and vote-support agreement ensure a clean annual meeting result on July 16, after which the share price catalyst shifts back to clinical/regulatory milestones for Vaxart's oral vaccine platform.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6200
T+0 close · Jul 6, 2026 · via day close
Latest settled
−26.77%
T+60 · $0.4540
Vs SPY
−28.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $0.6200entry
  2. T+1 · 4mo ago −11.24%α −10.77% · $0.5503
  3. T+5 · 4mo ago −13.84%α −13.56% · $0.5342
  4. T+20 · 4mo ago −4.84%α −5.69% · $0.5900
  5. T+60 · 7w ago −26.77%α −28.93% · $0.4540

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart and the Houle Stockholder Group entered into a Cooperation Agreement on July 1, 2026, ending the proxy contest for the July 16 annual meeting. The dissidents withdrew their three director nominations and books-and-records demand, and the board will adopt governance changes including a majority-vote resignation policy, stock ownership guidelines, new board committees, and a process to mutually appoint one independent director. The board's six nominees are now unopposed and the annual meeting vote is de-escalated to routine status.

Key Financial Metrics

Vote
director election
Meeting
2026-07-16
Seats Contested
0

Key Facts

  • Cooperation Agreement signed July 1, 2026 between Vaxart and Daniel P. Houle's Stockholder Group (Houle, Silverberg, Wallace, Raffy, Q3 Nominees, Pereira).
  • Dissidents withdrew all three director nominations and their books-and-records demand.
  • Within 60-90 days post-meeting, board will mutually agree with the Stockholder Group on one independent director (the 'New Director').
  • Board commits to adopt a resignation policy for directors receiving < majority votes in uncontested elections, directors' stock ownership guidelines, a Clinical and Regulatory Affairs Committee chaired by James Breitmeyer, a Stockholder Engagement Committee chaired by the New Director, and new committee chairs for NCG and Compensation.
  • Stockholder Group agreed to vote its shares in line with the board's recommendations and is subject to standstill and non-disparagement provisions.
  • Vaxart will reimburse up to $650,000 of the Stockholder Group's out-of-pocket expenses related to the proxy contest.
  • Previously submitted WHITE proxy cards remain valid, but votes for the three withdrawn dissident nominees will be disregarded.
  • Annual meeting remains July 16, 2026, record date unchanged at May 26, 2026.

Financial Impact

Vaxart agrees to reimburse up to $650,000 in expenses to the Stockholder Group; no other financial terms disclosed.

Risk Factors

  • If the 60-90 day process to appoint the New Director stalls or produces a weak candidate, the governance improvements may be viewed as cosmetic.
  • The standstill and non-disparagement provisions limit near-term activist pressure, removing a potential catalyst for operational change.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (VXRT), Batch item 10001213900-26-075169
Document: 0001213900-26-075169-index-headers.html0001213900-26-075169
Document: 0001213900-26-075169-index.html0001213900-26-075169
Document: 0001213900-26-075169.txt0001213900-26-075169
DEFA14A Filing (VXRT), Batch item 50001213900-26-075169
Document: 0001213900-26-075169-index-headers.html0001213900-26-075169
Document: 0001213900-26-075169-index.html0001213900-26-075169
Document: 0001213900-26-075169.txt0001213900-26-075169

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Viewing Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026